We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

340B Program: HRSA Posts Orphan Drug Exclusion Policy, PhRMA Responds

19 June 2014

Health, Pharmaceutical, and Biotechnology Alert

There have been a number of developments since the U.S. District Court for the District of Columbia “vacated,” or invalidated, HRSA’s final rule on the treatment of orphan drugs under the 340B Drug Discount Program. The Health Resources and Services Administration (HRSA), which administers the 340B program, issued the regulation in July 2013. It went into effect on October 1, 2013 and was vacated by the court on May 23, 2014, after a legal challenge brought by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read more: 340B Program: HRSA Posts Orphan Drug Exclusion Policy, PhRMA Responds

The team

Loading data